Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: primary outcomes from the randomized phase III OLIGO study

Oligometastatic breast cancer (OMBC) is a clinical entity with a prospect of long-term survival, but uncertainty remains on its optimal treatment. We studied whether intensified alkylating chemotherapy (IACT) improves long-term outcome compared to conventional-dose chemotherapy (CDCT) as part of a multimodality approach for patients with OMBC harboring homologous recombination deficiency (HRD).